Pfizer sues pharmas over arthritis drug patent


tribunal hearing legal case
If successful, action could hit pharmacy dispensed biosim Brenzys Multinational pharmaceutical giant Pfizer is suing four other drug companies over allegedly breaching a patent for its rheumatoid arthritis treatment Enbrel (etanercept) by selling biosimilars of the blockbuster drug. If ultimately successful it could potentially lead to the withdrawal of Brenzys, the first community pharmacy dispensed

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Why you should discuss flu vaccine choices with your patients this year
Next Leaked report shows UTI trial success